Skip to main content

Advertisement

Log in

The effectiveness and safety of liraglutide in treating overweight/obese patients with polycystic ovary syndrome: a meta-analysis

  • Review
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Purpose

The purpose of this study is to evaluate the effectiveness and safety of liraglutide/liraglutide + metformin in overweight/obese women with polycystic ovary syndrome (PCOS).

Methods

The related literatures published until April 2021 were searched in PubMed, Cochrane Library, MEDLINE and EmBase.

Results

Six randomized controlled trials of 127 related articles were obtained through searching. Three articles compared liraglutide with metformin, and four articles compared liraglutide combined with metformin with metformin. Our meta-analysis suggests that liraglutide was superior to metformin only in weight loss [MD = − 2.74, 95% CI (− 4.29, − 1.18), P = 0.0006]. Compared with metformin group, the combination group had significant advantages in weight loss [MD = − 3.81, 95% CI (− 5.16, − 2.46), P < 0.001], BMI [MD = − 2.59, 95% CI (− 3.12, − 2.07), P < 0.001], waist circumference [MD = − 6.26, 95% CI (− 7.79, − 4.72), P < 0.001], fasting blood glucose [MD = − 0.59, 95% CI (− 0.74, − 0.44), P < 0.001] and fasting insulin [MD = − 1.52, 95% CI (− 2.69, − 0.35), P = 0.01], while the incidence of adverse reactions was relatively high [RR = 2.91, 95% CI (1.55, 5.46), P = 0.00009].

Conclusion

The present results indicate that liraglutide and metformin have the similar effects in the treatment of overweight/obese PCOS patients. Liraglutide combined with metformin is more effective than metformin in improving PCOS, but it is necessary to master the correct medication method to reduce the occurrence of adverse reactions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Paschou SA, Polyzos SA, Anagnostis P, Goulis DG, Kanaka-Gantenbein C et al (2020) Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Endocrine 67:1–8

    Article  CAS  PubMed  Google Scholar 

  2. Norman RJ, Dewailly D, Legro RS, Hickey TE (2007) Polycystic ovary syndrome. Lancet 370:685–697

    Article  CAS  PubMed  Google Scholar 

  3. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised (2003) consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81:19–25

    Article  Google Scholar 

  4. Mahalingaiah S, Diamanti-Kandarakis E (2015) Targets to treat metabolic syndrome in polycystic ovary syndrome. Expert Opin Ther Targets 19:1561–1574

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Zeng X, Xie YJ, Liu YT, Long SL, Mo ZC (2020) Polycystic ovarian syndrome: correlation between hyperandrogenism, insulin resistance and obesity. Clin Chim Acta 502:214–221

    Article  CAS  PubMed  Google Scholar 

  6. Pepene CE, Ilie IR, Marian I, Duncea I (2011) Circulating osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in polycystic ovary syndrome: relationships to insulin resistance and endothelial dysfunction. Eur J Endocrinol 164:61–68

    Article  CAS  PubMed  Google Scholar 

  7. Krentowska A, Łebkowska A, Jacewicz-Święcka M, Hryniewicka J, Leśniewska M et al (2021) Metabolic syndrome and the risk of cardiovascular complications in young patients with different phenotypes of polycystic ovary syndrome. Endocrine 72(2):400–410

    Article  CAS  PubMed  Google Scholar 

  8. Ilie IR, Marian I, Mocan T, Ilie R, Mocan L et al (2012) Ethinylestradiol30μg-drospirenone and metformin: could this combination improve endothelial dysfunction in polycystic ovary syndrome? BMC Endocr Disord 12:9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, International PCOS Network et al (2018) Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod 33(9):1602–1618

    Article  PubMed  PubMed Central  Google Scholar 

  10. Palomba S, Falbo A, Zullo F, Orio F Jr (2009) Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev 30:1–50

    Article  CAS  PubMed  Google Scholar 

  11. Dunaif A (2008) Medicine insight: insulin-sensitizing medicines in the treatment of polycystic ovary syndrome-a reappraisal. Nat Clin Pract Endocrinol Metab 4:272–283

    Article  CAS  PubMed  Google Scholar 

  12. Diamanti-Kandarakis E, Christakou CD, Kandaraki E, Economou FN (2010) Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eur J Endocrinol 162:193–212

    Article  CAS  PubMed  Google Scholar 

  13. Lim SS, Davies MJ, Norman RJ, Moran LJ (2012) Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 18:618–637

    Article  CAS  PubMed  Google Scholar 

  14. Carmina E, Bucchieri S, Esposito A, Del Puente A, Mansueto P et al (2007) Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. J Clin Endocrinol Metab 92:2500–2515

    Article  CAS  PubMed  Google Scholar 

  15. Knudsen LB, Lau J (2019) The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne) 10:155

    Article  Google Scholar 

  16. Crosignani PG, Colombo M, Vegetti W, Somigliana E, Gessati A et al (2003) Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Hum Reprod 18:1928–1932

    Article  PubMed  Google Scholar 

  17. Zawadzki JK, Dunaif A (1992) Diagnostic criteria for polycystic ovary syndrome. In: Dunaif A, Haseltine F, Merriam GR (eds) Polycystic ovary syndrome. Blackwell Scientific Publications, Boston, pp 377–384

    Google Scholar 

  18. Higgins JPT, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Chichester, England

  19. Wang FF, Wu Y, Zhu YH, Ding T, Batterham RL (2018) Pharmacologic therapy to induce weight loss in women who have obesity/overweight with polycystic ovary syndrome: a systematic review and network meta-analysis. Obes Rev 19:1424–1445

    Article  PubMed  Google Scholar 

  20. Jensterle M, Salamun V, Kocjan T, Vrtacnik Bokal E, Janez A (2015) Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study. J Ovarian Res 8:32

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  21. Jensterle Sever M, Kocjan T, Pfeifer M, Kravos NA, Janez A (2014) Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur J Endocrinol 170:451–459

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  22. Jensterle M, Kravos NA, Pfeifer M, Kocjan T, Janez A (2015) A 12-week treatment with the long-acting GLP-1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome. Hormones (Athens) 14:81–90

    Article  Google Scholar 

  23. Salamun V, Jensterle M, Janez A, Vrtacnik Bokal E (2018) Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. Eur J Endocrinol 179:1–11

    Article  CAS  PubMed  Google Scholar 

  24. Jensterle M, Kravos NA, Goricar K, Janez A (2017) Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial. BMC Endocr Disord 17:5

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  25. Huang ZS, Luan LL, Yang J, Huang ZX, Wang CY et al (2015) Efficacy of liraglutide on metabolic parameters and pregnancy in polycystic ovary syndrome patients combined with impaired glucose tolerance and obesity. Chin J Diabetes Mellitus 7:437–441 (in Chinese)

    CAS  Google Scholar 

  26. Chou KH, von Eye CH, Capp E, Spritzer PM (2003) Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial. Horm Metab Res 35:86–91

    Article  CAS  PubMed  Google Scholar 

  27. Naderpoor N, Shorakae S, de Courten B, Misso ML, Moran LJ et al (2015) Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. Hum Reprod Update 21:560–574

    Article  CAS  PubMed  Google Scholar 

  28. De Sloover KY, Ernst ME (2001) Use of metformin in polycystic ovary syndrome. Ann Pharmacother 35:1644–1647

    Article  Google Scholar 

  29. Ladenheim EE (2015) Liraglutide and obesity: a review of the data so far. Drug Des Devel Ther 9:1867–1875

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Meier JJ (2012) GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 8:728–742

    Article  CAS  PubMed  Google Scholar 

  31. Dailey MJ, Moran TH (2013) Glucagon-like peptide 1 and appetite. Trends Endocrinol Metab 24:85–91

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Van Bloemendaal L, Ten Kulve JS, la Fleur SE, Ijzerman RG, Diamant M (2014) Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol 221:T1-16

    Article  PubMed  CAS  Google Scholar 

  33. Marathe CS, Rayner CK, Jones KL, Horowitz M (2011) Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function. Exp Diabetes Res 2011:279530

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  34. Rachoń D, Teede H (2010) Ovarian function and obesity–interrelationship, impact on women’s reproductive lifespan and treatment options. Mol Cell Endocrinol 316:172–179

    Article  PubMed  CAS  Google Scholar 

  35. Cena H, Chiovato L, Nappi RE (2020) Obesity, polycystic ovary syndrome, and infertility: a new avenue for GLP-1 receptor agonists. J Clin Endocrinol Metab 105:e2695–e2709

    Article  PubMed Central  Google Scholar 

  36. Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Franks S et al (2014) The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur J Endocrinol 171:P1–P29

    Article  CAS  PubMed  Google Scholar 

  37. Niafar M, Pourafkari L, Porhomayon J, Nader N (2016) A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries. Arch Gynecol Obstet 293:509–515

    Article  CAS  PubMed  Google Scholar 

  38. Frøssing S, Nylander M, Chabanova E, Frystyk J, Holst JJ et al (2018) Effect of liraglutide on ectopic fat in polycystic ovary syndrome: a randomized clinical trial. Diabetes Obes Metab 20:215–218

    Article  PubMed  CAS  Google Scholar 

  39. Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R (2008) Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 93:2670–2678

    Article  CAS  PubMed  Google Scholar 

  40. Hoang V, Bi J, Mohankumar SM, Vyas AK (2015) Liraglutide improves hypertension and metabolic perturbation in a rat model of polycystic ovarian syndrome. PLoS ONE 10:e0126119

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  41. Gadde KM, Martin CK, Berthoud HR, Heymsfield SB (2018) Obesity: pathophysiology and management. J Am Coll Cardiol 71(1):69–84

    Article  PubMed  PubMed Central  Google Scholar 

  42. Jensterle M, Kravos NA, Goričar K, Janez A (2017) Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial. BMC Endocr Disord 17(1):5

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  43. Siamashvili M, Davis SN (2021) Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome. Expert Rev Clin Pharmacol 27:1–9

    Google Scholar 

  44. Papaetis GS, Filippou PK, Constantinidou KG, Stylianou CS (2020) Liraglutide: new perspectives for the treatment of polycystic ovary syndrome. Clin Drug Investig 40(8):695–713

    Article  PubMed  Google Scholar 

Download references

Funding

This research did not receive any specific grant from funding agencies.

Author information

Authors and Affiliations

Authors

Contributions

J. J. Ge and D. J. Wang wrote the manuscript. J. J. Ge and W. Song analyzed data. S. M. Shen and W. H. Ge edited and approved this manuscript.

Corresponding authors

Correspondence to S. M. Shen or W. H. Ge.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Ethical approval

This article does not include research on human participants and/or animals.

Informed consent

Informed consent is not required.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ge, J., Wang, D., Song, W. et al. The effectiveness and safety of liraglutide in treating overweight/obese patients with polycystic ovary syndrome: a meta-analysis. J Endocrinol Invest 45, 261–273 (2022). https://doi.org/10.1007/s40618-021-01666-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-021-01666-6

Keywords

Navigation